Moderna (NASDAQ:MRNA) Earns “Market Perform” Rating from William Blair

William Blair reiterated their market perform rating on shares of Moderna (NASDAQ:MRNA) in a report published on Thursday morning, RTT News reports.

Several other research analysts have also weighed in on the stock. Piper Sandler restated an overweight rating and set a $214.00 price objective on shares of Moderna in a research note on Thursday. Jefferies Financial Group restated a buy rating and set a $125.00 price objective on shares of Moderna in a research note on Tuesday, April 9th. UBS Group boosted their price objective on shares of Moderna from $143.00 to $151.00 and gave the stock a buy rating in a research note on Tuesday, May 7th. Royal Bank of Canada boosted their price objective on shares of Moderna from $135.00 to $160.00 and gave the stock an outperform rating in a research note on Monday, June 3rd. Finally, Needham & Company LLC reiterated a hold rating on shares of Moderna in a research note on Monday, June 3rd. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of Hold and an average price target of $134.02.

Moderna Stock Down 2.0 %

Shares of MRNA stock opened at $118.75 on Thursday. The company has a current ratio of 4.03, a quick ratio of 3.91 and a debt-to-equity ratio of 0.04. Moderna has a 1 year low of $62.55 and a 1 year high of $170.47. The firm’s fifty day moving average price is $134.13 and its two-hundred day moving average price is $111.96. The firm has a market capitalization of $45.51 billion, a P/E ratio of -7.58 and a beta of 1.54.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Thursday, May 2nd. The company reported ($3.07) earnings per share for the quarter, topping the consensus estimate of ($3.59) by $0.52. The company had revenue of $167.00 million for the quarter, compared to analyst estimates of $93.26 million. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. Moderna’s revenue for the quarter was down 91.0% compared to the same quarter last year. During the same period in the previous year, the business earned $0.19 EPS. On average, equities analysts predict that Moderna will post -7.46 EPS for the current fiscal year.

Insider Buying and Selling at Moderna

In other news, Director Noubar Afeyan sold 202,832 shares of the company’s stock in a transaction that occurred on Tuesday, June 11th. The shares were sold at an average price of $148.34, for a total transaction of $30,088,098.88. Following the completion of the sale, the director now owns 1,528,557 shares of the company’s stock, valued at approximately $226,746,145.38. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, President Stephen Hoge sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, June 17th. The shares were sold at an average price of $138.16, for a total transaction of $2,072,400.00. Following the completion of the sale, the president now owns 1,457,089 shares of the company’s stock, valued at approximately $201,311,416.24. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Noubar Afeyan sold 202,832 shares of the company’s stock in a transaction that occurred on Tuesday, June 11th. The stock was sold at an average price of $148.34, for a total transaction of $30,088,098.88. Following the sale, the director now directly owns 1,528,557 shares of the company’s stock, valued at approximately $226,746,145.38. The disclosure for this sale can be found here. Insiders sold 411,255 shares of company stock valued at $56,118,931 in the last quarter. Company insiders own 15.70% of the company’s stock.

Institutional Trading of Moderna

A number of institutional investors and hedge funds have recently made changes to their positions in MRNA. Ogorek Anthony Joseph NY ADV bought a new position in Moderna in the 4th quarter valued at approximately $27,000. Cedar Wealth Management LLC lifted its stake in Moderna by 45.0% in the 1st quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock valued at $31,000 after purchasing an additional 90 shares during the last quarter. Arlington Trust Co LLC lifted its stake in Moderna by 4,833.3% in the 4th quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock valued at $29,000 after purchasing an additional 290 shares during the last quarter. Westside Investment Management Inc. bought a new position in Moderna in the 1st quarter valued at approximately $32,000. Finally, Rise Advisors LLC lifted its stake in Moderna by 953.3% in the 1st quarter. Rise Advisors LLC now owns 316 shares of the company’s stock valued at $34,000 after purchasing an additional 286 shares during the last quarter. Institutional investors own 75.33% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.